← Back to Search

Herbal Supplement

Angelica Gigas Supplement for Immune Function

N/A
Waitlist Available
Led By Junxuan Lu, Ph.D.
Research Sponsored by Milton S. Hershey Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects weighing between 110 to 240 pounds with a body mass index (BMI) in the range of 19 to 30
Subjects having normal hepatic, renal function as assessed by history, physical and clinical chemistry analysis (CMP eGFR, see supporting document for normal reference ranges)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 70 days
Awards & highlights

Study Summary

This trial will test the effects of a dietary supplement containing Korean Angelica root extract on human immune cells.

Who is the study for?
This trial is for adults weighing 110 to 240 pounds with a BMI of 19-30, normal liver and kidney function, and blood pressure below the high range. It's not for those with HIV/HBV/HCV, on regular prescription meds or who have major health issues like diabetes or severe organ diseases. Smokers, heavy drinkers, non-English speakers, and users of certain supplements can't join.Check my eligibility
What is being tested?
The study tests if Korean Angelica root extract (Cogni.Q) boosts immune cells compared to a placebo. Participants will take either Cogni.Q vegicaps or dummy pills without knowing which one they're getting. The focus is on whether this supplement increases neutrophils and NK cells that fight infections and cancer.See study design
What are the potential side effects?
Since this trial involves dietary supplements rather than drugs, side effects might be milder but could include digestive discomfort or allergic reactions specific to the ingredients in the Korean Angelica root extract.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I weigh between 110 to 240 pounds and my BMI is between 19 to 30.
Select...
My liver and kidney functions are normal.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~70 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 70 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Neutrophil counts and NK cell counts in peripheral blood
Secondary outcome measures
CMP-EGFR
Lipid profiling
NK mRNA signature
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Cogni.QExperimental Treatment2 Interventions
800 mg per day (Two 200 mg capsules in the morning and two 200 mg capsules in the evening) for 21 days
Group II: PlaceboPlacebo Group2 Interventions
Two capsules in the morning and two capsules in the evening for 21 days

Find a Location

Who is running the clinical trial?

Milton S. Hershey Medical CenterLead Sponsor
497 Previous Clinical Trials
2,799,930 Total Patients Enrolled
Junxuan Lu, Ph.D.Principal Investigator - Penn State College of Medicine
Milton S. Hershey Medical Center

Media Library

Cogni.Q (Herbal Supplement) Clinical Trial Eligibility Overview. Trial Name: NCT03630328 — N/A
Innate Immune Cells Research Study Groups: Cogni.Q, Placebo
Innate Immune Cells Clinical Trial 2023: Cogni.Q Highlights & Side Effects. Trial Name: NCT03630328 — N/A
Cogni.Q (Herbal Supplement) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03630328 — N/A
~7 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top